Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Key Highlights
- ➤Peter Anastasiou becomes Harmony CEO and president effective January 1, 2027
- ➤Jeffrey M. Dayno retires December 31, 2026, then advises Harmony through 2027
- ➤WAKIX 2026 net revenue guidance reiterated at $1.0 billion to $1.04 billion
- ➤BP-205 MAD study data remains on track for Q4 2026
Expert Statements
Jeffrey S. Aronin, Founder and Chairman of the Board of Harmony Biosciences
“Jeff has led Harmony through a period of strong growth, establishing WAKIX as a leading treatment in narcolepsy, advancing the pitolisant lifecycle management strategy, diversifying the pipeline for sustained long-term growth and leaving the Company in a position of financial strength.”
Jeffrey S. Aronin, Founder and Chairman of the Board of Harmony Biosciences
“The Board is grateful for Jeff’s leadership and his commitment to patients, employees and shareholders.”
Jeffrey S. Aronin, Founder and Chairman of the Board of Harmony Biosciences
“Peter is the right leader for Harmony’s next phase of growth. He has a deep understanding of our business and has been an important contributor to our strategy, pipeline and business development efforts.”
Jeffrey S. Aronin, Founder and Chairman of the Board of Harmony Biosciences
“Peter also brings more than three decades of biopharmaceutical experience, leading organizations in commercializing, acquiring and developing treatments for both broad and rare CNS diseases to serve patients and create value for shareholders.”
Jeffrey M. Dayno, President and CEO of Harmony Biosciences
“It has been a privilege to lead Harmony through a phase of significant growth, and I am grateful to the Board for the opportunity to have served as CEO. It has also been my honor to work alongside such a talented team of individuals who are deeply committed to improving the lives of patients with unmet needs.”
Jeffrey M. Dayno, President and CEO of Harmony Biosciences
“Peter knows Harmony’s business exceptionally well, I have great confidence in his leadership, and I look forward to supporting him, the Board and the Company through this transition.”
Peter Anastasiou, President and CEO-designate of Harmony Biosciences
“I am honored to serve as Harmony’s next CEO and am grateful to the Board for this opportunity. Harmony is unique, having strong commercial capabilities, a diverse CNS pipeline with multiple potential value-creating catalysts, and a strong balance sheet that allows us to be self-funded and to invest thoughtfully in additional opportunities.”
Peter Anastasiou, President and CEO-designate of Harmony Biosciences
“I look forward to working with the Board, leadership team and our dedicated employees to lead Harmony through our next phase of growth, building on the foundation that Jeff and the team have established.”
The Board of Directors has appointed Peter Anastasiou, former Harmony board member and current Sr. EVP and COO, to become President, Chief Executive Officer and a member of the Board, effective January 1, 2027.
Current CEO Jeffrey M. Dayno, M.D., will retire at the end of the year following a nine-year tenure at the Company, including as Chief Medical Officer, and step down as a member of the Board.
Get started
Create a free account to read the full story.